A perfect four-quarter earnings beat streak averaging nearly 60% above estimates, a forward multiple of 7.2x with a PEG of 0.18, and analyst consensus implying 31% upside build a compelling fundamental case — tempered by a confirmed price downtrend, an unusually elevated put/call ratio, and a spot reward-to-risk ratio that narrowly misses the entry threshold.
Thesis pillars
- Perfect Earnings Beat Streak↑Improving
- Deep Value Analyst Conviction↓Deteriorating
- Confirmed Downtrend In Price↑Improving
- +1 more pillar — see the Why tab for full reasoning
Ardent Health, Inc. (ARDT) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Care Facilities
Hold if already holding. Not a fresh buy at $9.75, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.3): -0.5.
Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, often through majority-owned joint ventures with academic medical centers, non-profit... Read more
Hold if already holding. Not a fresh buy at $9.75, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.3): -0.5. Chart setup: Death cross but MACD improving, RSI 46. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Ardent Health, Inc.
About Ardent Health, Inc.
Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, serving roughly 17,000 patients daily and 1.2 million unique patients with more than 6.1 million visits in 2025. Private third-party payors accounted for 44.3% of Ardent's revenue in 2025, up slightly from 43.5% in 2024, with the remainder derived largely from Medicare and Medicaid.
Ardent runs 18 of its 30 hospitals through majority-owned joint ventures with academic medical centers, not-for-profit health systems, and physician groups, retaining majority economic and governance control while partners hold minority stakes and, in several cases, veto rights tied to maintaining 501(c)(3) community-benefit status. Revenue comes from inpatient and ambulatory care, including 188 primary and specialty clinics, 45 urgent care centers, and four ambulatory surgery centers, billed to Medicare, Medicaid, and private commercial payors under negotiated in-network contracts. The company holds the leading or second-leading inpatient market share in most of its markets, led by Hackensack Meridian Medical Centers in New Jersey at 51.7% share and BSA Health System in Amarillo, Texas at 53.6% share, and has invested nearly $32.7 million over three years in technology, including a system-wide Epic electronic health record platform and AI-based patient-monitoring wearables.
Show full overview
Ardent's facilities are heavily concentrated in Texas and Oklahoma, home to 21 of its 30 hospitals, leaving the system exposed to state-level Medicaid assessment changes, regional labor-cost swings, and severe-weather disruption in a way a more geographically dispersed peer would not be. That concentration compounds a structural governance constraint: 18 of Ardent's hospitals operate through joint ventures where partner-appointed directors hold block-voting rights and, in several agreements, unilateral authority to terminate the management services agreement if Ardent's operations are seen as jeopardizing a partner's nonprofit community-benefit status, meaning Ardent's day-to-day operating control over a majority of its hospital count is contractually conditioned rather than absolute.
See also: Healthcare · Medical Care Facilities
From Ardent Health, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — Ardent Health, Inc.
Latest news
- NEWS Ardent Health Q1 2026 slides: 26% EBITDA growth, stock falls By Investing.com - Investing.com Australia — Investing.com Australia negative
- NEWS Ardent Health Q1 2026 slides: 26% EBITDA growth, stock falls By Investing.com - Investing.com South Africa — Investing.com South Africa negative
- NEWS Ardent Health Q1 2026 slides: 26% EBITDA growth, stock falls - Investing.com — Investing.com negative
- NEWS BofA raises Ardent Health stock price target on strong Q1 results - Investing.com Canada — Investing.com Canada positive
- NEWS Ardent Health, Inc. (ARDT) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-07-26T23:07:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicTexas and Oklahoma10-K Item 1A: 'our facilities are heavily concentrated in Texas and Oklahoma, which makes us sensitive to regulatory, economic and competitive conditions and changes in those states'
- MEDIUMCustomerprivate third party payors44%10-K Item 1A: 'Revenues derived from private third party payors accounted for 44.3% and 43.5% of our revenues for 2025 and 2024, respectively.'
Material Events(8-K, last 90d)
- 2026-06-02Item 5.02MEDIUMPresident and CEO Martin J. Bonick departed effective June 2, 2026; the Board immediately appointed COO Dave Caspers as President and CEO and a director, a clean handoff with an internal successor named the same day.SEC filing →
- 2026-06-30Item 5.02LOWFollow-up filing disclosing that departed CEO Martin J. Bonick entered a Separation Agreement on June 26, 2026 providing severance benefits consistent with a termination without Cause, formalizing the previously disclosed departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $9.75, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.3): -0.5. Chart setup: Death cross but MACD improving, RSI 46. Maintain position. Not compelling to add more. Target $11.34 (+16.3%), stop $9.90 (−-1.5%), A.R:R -0.1:1. Score 6.4/10, moderate confidence.
Take-profit target: $11.34 (-1.5% upside). Target $11.34 (+16.3%), stop $9.90 (−-1.5%), A.R:R -0.1:1. Stop-loss: $9.90.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.3): -0.5.
Ardent Health, Inc. trades at a P/E of 11.3 (forward 8.5). TrendMatrix value score: 8.2/10. Verdict: Hold.
18 analysts cover ARDT with a consensus score of 3.9/5. Average price target: $12.
What does Ardent Health, Inc. do?Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban...
Ardent Health operates 30 acute care hospitals and more than 280 additional sites of care across eight mid-sized urban markets in Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas, often through majority-owned joint ventures with academic medical centers, non-profit health systems, and physician groups. The company earns revenue from inpatient and ambulatory patient care reimbursed by Medicare, Medicaid, and private third-party payors, with private payors accounting for 44.3% of 2025 revenue, and named Dave Caspers as President and CEO in June 2026 after Martin Bonick's departure.